title: Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy.
abstract: Blinatumomab is a member of a novel class of T cell-engaging bispecific antibodies, so-called Bispecific T cell Engager (BiTEs). It is directed against the B cell differentiation antigen CD19 and intended for treatment of B cell malignancies. In clinical phase I/II trials, blinatumomab showed remarkable single-agent activity in patients with relapsed and/or refractory (R/R) non-Hodgkin lymphoma and R/R B cell precursor acute lymphoblastic leukemia (B-precursor ALL). Cytokine release syndrome and neurological side effects were dose-limiting. Adverse effects were well manageable and transient in nature. Based on results of an international phase II trial, blinatumomab received FDA approval for the treatment of R/R B-precursor ALL in December 2014. Ongoing and future trials will contribute to further optimization of blinatumomab-based T cell therapy and have to show that integration of blinatumomab in current and innovative treatment protocols improves overall survival and quality of life of patients with B cell malignancies.
authors.affiliation: a Comprehensive Cancer Center Mainfranken, University Hospital Würzburg , Würzburg , Germany ;|b Department of Internal Medicine II , University Hospital Würzburg , Würzburg , Germany.
authors.forename: Maria-Elisabeth
authors.initials: ME
authors.lastname: Goebeler
authors.affiliation: a Comprehensive Cancer Center Mainfranken, University Hospital Würzburg , Würzburg , Germany ;
authors.forename: Ralf
authors.initials: R
authors.lastname: Bargou
mesh_terms: D000818:Animals; D018033:Antibodies, Bispecific / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*; D018941:Antigens, CD19 / Q000378:metabolism; D000970:Antineoplastic Agents / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*; D017252:CD3 Complex / Q000378:metabolism; D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D004353:Drug Evaluation, Preclinical; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D012008:Recurrence; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D018033:Antibodies, Bispecific; D018941:Antigens, CD19; D000970:Antineoplastic Agents; D017252:CD3 Complex; C510808:blinatumomab
keywords: B-precursor ALL; BiTE®; NHL; blinatumomab; immunotherapy